Skip to main content

Table 4 Faecal concentrations of SMT19969 following single oral doses (Part 1)

From: A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections

Group

Dose

Mean (min – max) faecal concentrations (μg/g)

Time post dose (hours)

0-24

24-48

48-72

C

100 mg

20 (<20 – 20)

213 (<20 – 330)

210 (<20 – 598)

D

400 mg

239 (<20 – 317)

1,132 (<20 – 3,340)

677 (436 – 948)

E TP1

1,000 mg

1,194 (<20 – 2,310)

855 (305 – 1,040)

1,209 (183 – 1,970)

F

2,000 mg

<20 (<20 – <20)

5713 (<20 – 11,800)

6,478 (1,030 – 17,600)